Sanofi - ADR (SNY): Price and Financial Metrics


Sanofi - ADR (SNY)

Today's Latest Price: $48.68 USD

1.19 (2.51%)

Updated May 28 6:55pm

Add SNY to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 214 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

SNY Stock Summary

  • SNY has a higher market value than 98.7% of US stocks; more precisely, its current market capitalization is $122,072,560,697.
  • With a price/earnings ratio of 40.02, Sanofi P/E ratio is greater than that of about 81.1% of stocks in our set with positive earnings.
  • The volatility of Sanofi's share price is greater than that of merely 1.24% US stocks with at least 200 days of trading history.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Sanofi are GSK, AMGN, MDT, BMY, and DHR.
  • Visit SNY's SEC page to see the company's official filings. To visit the company's web site, go to www.sanofi.com.
SNY Daily Price Range
SNY 52-Week Price Range

SNY Stock Price Chart More Charts


SNY Price/Volume Stats

Current price $48.68 52-week high $51.84
Prev. close $47.49 52-week low $37.62
Day low $47.96 Volume 1,763,500
Day high $49.12 Avg. volume 2,330,334
50-day MA $46.13 Dividend yield 2.4%
200-day MA $46.76 Market Cap 121.90B

Sanofi - ADR (SNY) Company Bio


Sanofi researches, develops, manufactures, and markets various therapeutic solutions. The company operates in three segments: Pharmaceuticals, Vaccines, and Animal Health. The company was founded in 1973 and is based in Paris, France.

SNY Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target:Forecasted Gain:
$48.68$68.9545%

Below please find a table outlining a discounted cash flow forecast for SNY, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Sanofi ranked in the 57th percentile in terms of potential gain offered. Moreover, under all the scenarios we modelled, the output consistently forecasted positive returns. The most interesting components of our discounted cash flow analysis for Sanofi ended up being:

  • In the past 4.99 years, Sanofi has a compound free cash flow growth rate of 0.02%; that's higher than merely 23.81% of free cash flow generating stocks in the Healthcare sector.
  • Sanofi's weighted average cost of capital (WACC) is 7%; for context, that number is higher than just 12.16% of tickers in our DCF set.
  • SNY's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than just 12.16% of tickers in our DCF set.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%42%
1%44%
2%45%
3%47%
4%48%
5%49%

For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as SNY, try DRRX, UHS, PBH, AHPI, and MEDP.


SNY Latest News Stream


Event/TimeNews Detail
Loading, please wait...

SNY Latest Social Stream


Loading social stream, please wait...

View Full SNY Social Stream

Latest SNY News From Around the Web

Below are the latest news stories about Sanofi that investors may wish to consider to help them evaluate SNY as an investment opportunity.

The Daily Biotech Pulse: Cumberland's Positive Anti-Bacterial Readout, FDA Nods For Bristol-Myers, Astellas

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 26) ADC Therapeutics SA (NYSE: ADCT ) (IPOed May 15) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE )(announced positive one-year Phase 1/2 study and Phase 2 open-label extension study of pegzilarginase in Arginase 1 Deficiency patients) Allogene Therapeutics Inc (NASDAQ: ALLO ) Altimmune Inc (NASDAQ: ALT ) argenx SE – ADR (NASDAQ: ARGX )( announced positive top-line data from a late-stage study of efgartigimod in patients with generalized Myasthenia Gravis) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN )(gained on sell-side comment on the company being a potential target for Sanofi SA (NASDAQ: SNY ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) Castle Bioscien...

Benzinga | May 27, 2020

Insulin Market Report 2020: Includes Revenue Data (2013-2022) for Novo Nordisk, Sanofi Aventis, Eli Lilly, Merck & Co, and Beckton Dickinson

DUBLIN, May 27, 2020 /PRNewswire/ -- The "Global Insulin Market - Focus on Insulin Delivery Devices [By Devices - Vials & Syringes, Insulin Pens, Insulin Pumps, Insulin Jet Injectors; By Region - North America (The US), Europe (The UK, Germany, France & Italy) and Asia Pacific (Japan,…

PR Newswire | May 27, 2020

Amid the COVID-19 Pandemic, Neurologists in Canada Report Pulling Back from EMD Serono's Mavenclad and Sanofi Genzyme's Lemtrada, While Roche's Ocrevus Stalls, According to Spherix Global Insights

EXTON, Pa. , May 27, 2020 /PRNewswire/ -- The COVID-19 pandemic has (at least temporarily) transformed neurology practices and multiple sclerosis (MS) patient management patterns across Canada , according to the most recent report included in Spherix's RealTime Dynamix™: Multiple Sclerosis ( Canada ) service. The report, which collected the responses of 50 Canadian neurologists surveyed between April 6 th and May 2 nd , found that 90% of respondents indicate the novel coronavirus outbreak has had a high impact on their practice. While preference for induction versus escalation treatment was clearly on the rise prior to the pandemic, new data suggest a potentially transient reversion to more conservative disease-modifying therapy (DMT) treatment patterns. Neurologists express hesitation ...

Benzinga Feeds | May 27, 2020

Drugmaker Sanofi to raise over US$11 billion via sale of Regeneron shares

Sanofi will raise over US$11 billion from the sale of 21.6 million shares in its U.S. partner Regeneron, the French drugmaker said on Wednesday, adding it would use the proceeds for innovation and general growth.

Channel NewsAsia | May 27, 2020

Sanofi's Dupixent Gets FDA Approval for Eczema in Children

Sanofi (SNY) secures an FDA nod for Dupixent as the first biologic medicine for children aged from six to 11 years with moderate-to-severe atopic dermatitis.

Zacks Investment Research | May 27, 2020

Read More 'SNY' Stories Here

SNY Price Returns

1-mo 1.79%
3-mo 7.84%
6-mo 6.84%
1-year 22.18%
3-year 12.27%
5-year 17.19%
YTD -0.65%
2019 23.73%
2018 4.20%
2017 8.73%
2016 -2.52%
2015 -3.37%

SNY Dividends

Ex-Dividend DateTypePayout AmountChange
Loading, please wait...
View Full SNY Dividend History

Continue Researching SNY

Want to see what other sources are saying about Sanofi's financials and stock price? Try the links below:

Sanofi (SNY) Stock Price | Nasdaq
Sanofi (SNY) Stock Quote, History and News - Yahoo Finance
Sanofi (SNY) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7629 seconds.